A Virus, Read Closely: Skinjo Interviews Iris on Bacteriophages

A Virus, Read Closely

Afternoon light crosses Skinjo’s sketchbook. Beside an outline of a cell, there is room for a second drawing. Iris sits opposite as Skinjo turns back to the question left by the earlier publication on plasmolysis: what is the cell wall really doing, and what are we only assuming from its outline?

Skinjo: In plasmolysis, the membrane can pull away from the wall as the cell loses water. The boundary still looks like a boundary, but the picture needs an explanation. Now we have another image that seems to contradict itself: a virus as a healer. How could that work?

Iris: By asking which cells the virus can infect. Bacteriophages—phages for short—infect bacteria, not human cells. WHO’s European office describes them as highly specific. A phage does not simply recognize “an infection” and remove it. It needs a susceptible bacterial host.

Skinjo: So “bacteria-targeting” is not the same as “targets every bacterium.”

Iris: Exactly. The match can be narrow, even among strains of the same bacterial species. For phages that kill their hosts, infection turns the bacterium’s machinery toward making more phages; the bacterial cell can then rupture and release them. That is a different event from plasmolysis. A membrane withdrawing from a wall is not the same thing as a cell being broken open.

Skinjo draws two separate frames rather than one continuous arrow.

Skinjo: Where do antibiotic-resistant bacteria enter this picture?

Iris: Resistance to an antibiotic does not automatically mean resistance to a phage. They act differently, so a suitable phage can kill bacteria that withstand particular antibiotics. That possibility has renewed interest in an older approach. But it is not a universal override. Matching still matters, and bacteria can also develop resistance to phages.

Skinjo: The need is enormous. Can we put a number beside it without making the number promise more than the research does?

Iris: WHO Europe’s fact sheet, dated 17 February 2025, says antimicrobial resistance is directly responsible for 133,000 deaths each year in the WHO European Region and indirectly linked to 541,000. Those are regional figures about antimicrobial resistance—not counts of people phages have saved, or could certainly save. We should not add them together as though they were separate groups.

Skinjo: And yet “used in patients” can sound like “already proven.”

Iris: That is the important distinction. WHO says phages are currently used mainly on compassionate grounds, when other treatments have been exhausted. Compassionate use responds to an urgent individual situation with limited options. It does not, by itself, establish a treatment as safe and effective for routine use.

Skinjo: Even if someone improves?

Iris: An improvement matters. So does knowing what caused it. An individual case cannot, on its own, separate the effects of the phages from other treatments or the course of the illness. It cannot tell us reliably how often the approach will help other people, or what risks might appear across a larger group. WHO calls for more clinical evidence on efficacy, safety and feasibility before wide human use.

Skinjo: Then “does not infect human cells” is a precise statement, not a complete safety certificate.

Iris: Yes. It describes host specificity. It does not settle every question about a therapeutic preparation or its effects. Promise and proof are different kinds of information.

Skinjo leaves the space between the two drawings unpainted.

Skinjo: Our earlier cell wall needed a closer reading. This does too: not “virus equals harm,” and not “virus equals cure,” but which virus, which bacterium, and what evidence?

Iris: A possibility worth investigating carefully. The urgency is real; so is the need to find out what works.

Source: WHO Regional Office for Europe, “Bacteriophages and their use in combating antimicrobial resistance,” 17 February 2025. https://www.who.int/europe/news-room/fact-sheets/item/bacteriophages-and-their-use-in-combating-antimicrobial-resistance

This interview is an educational discussion, not medical advice.